Investigator Led Studies (ILS), also known as Investigator Initiated Studies (IIS), are independent research projects that are initiated and managed by investigators. ILS are conceived, designed, and executed by the investigator, who assumes the role of sponsor. In ILS arrangements, Revvity typically provides product support, scientific collaboration, or other resources without taking on sponsorship responsibilities. As the study sponsor, the investigator must ensure that all legal and regulatory requirements are met and that the study is conducted and managed in accordance with all applicable laws and regulations.
Revvity's ILS program overview
We understand that discoveries emerge when independent researchers explore transformative ideas. Through our ILS program, we would provide ILS governance review and support and offer comprehensive tailored support including:
- Diagnostic products
- Research reagents
- Strategic grant funding
- Advanced instrumentation on a case-by-case basis
ILS research support empowers independent researchers to transform promising ideas into impactful discoveries and help improve patients' outcomes.
Our strategic partnership capitalizes on each participating site's specialties, competencies, and clinical datasets. The ILS partnership model provides Revvity with:
- Review of Proposals: Evaluation of research proposals within ILS timeframes.
- Investigator Study Updates: Ongoing investigator reports throughout the ILS lifecycle.
- Shared Study Data: Data sharing as defined within the ILS agreement and applicable regulations.
- Manuscripts/Publications: Review of manuscripts for accuracy and protection of confidential information in accordance with the ILS agreement prior to submission.
Our areas of interest
Revvity's ILS program is open to qualified researchers who are interested in conducting studies which aim to broaden clinical and scientific insights and deepen understanding of our solutions within the priority therapeutic areas listed below.
Tuberculosis (T-SPOT™.TB)
- Tuberculosis infection testing
- Non-TB mycobacteria infection testing
Cytomegalovirus (T-SPOT™.CMV)
- Interventional studies
- Congenital CMV
- Transplant
Other studies
Studies to explore performance of T-SPOT technology-based tests.
Who can participate in Revvity's ILS program?
Clinicians affiliated with hospitals, health systems, or private practices
Academic researchers or investigators from universities or research institutions
Clinical fellows or postdoctoral researchers (with institutional oversight)
Multi-disciplinary teams conducting collaborative studies
The ILS process
Check your eligibility
- Appropriate infrastructure and resources in place to conduct the proposed study i.e., scientific, technical, statistical, operational capabilities, and trained staff.
- Have obtained IRB/Ethics approval or prepared to secure approval following ILS proposal approval.
- Clinical research experience evidenced by CV, GCP training, etc.
- Able to meet all regulatory requirements (e.g., final study reports and manuscripts) and to publish in a peer-reviewed scientific journal.
Submit your proposal
Click "I want to submit a proposal" to access our ILS proposal form. Please download the form, complete it in full, and submit to researchstudies_idx@revvity.com.
Submission requirements:
- Ensure your study objectives align with our areas of interest.
- Include all required supporting documentation: protocol, CV, IRB approval (if available), budget (if applicable), W-9 (if receiving funding).
- All documents submitted must be in the English language.
Internal review
- All proposals undergo evaluation by Revvity's Investigator-Led Study Committee.
- The committee assesses scientific merit, feasibility, and strategic alignment.
- The final project review timeline will be defined during proposal discussion.
Feedback and clarifications
The ILS program internal review process will evaluate the following:
- Scientific rigor and innovation
- Alignment with our therapeutic areas and research objectives
- Feasibility of study design and timeline
- Potential for meaningful clinical or scientific impact
Following the committee's monthly review, you will receive notification of the decision along with feedback and, if approved, details regarding support parameters and collaboration terms will be provided.
Final approval and agreement
- Approval: If your proposal is approved, you will receive a formal agreement outlining support parameters, deliverables, timelines, and collaboration terms.
- Agreement finalization and execution: Both parties must sign before study initiation
- Support activation: Resources and materials are provided per agreed terms.
All approved studies require executed agreements before any support begins.
Launch and collaboration
Following committee approval, we initiate a structured collaboration process:
- Study launch - Activate resources, materials, and dedicated support team upon agreement execution.
- Ongoing collaboration - Establish regular communication channels, progress reviews, and milestone checkpoints with assigned Revvity liaison.
- Knowledge sharing - Participate in periodic collaboration meetings and contribute to our research community.
Frequently Asked Questions
-
What is the difference between ILS and Investigator-Initiated Studies (IIS)?
ILS (Investigator-Led Studies) and IIS (Investigator-Initiated Studies) are synonymous terms that describe clinical research conceived, initiated, and managed by independent researchers who serve as both investigator and sponsor. Both terms represent studies where the researcher has primary responsibility rather than a commercial sponsor.
-
What types of studies are eligible for ILS consideration?
Studies with on-label product indications and valid study proposals that align with Revvity's strategic areas of interest are eligible for consideration. Currently, we are accepting applications exclusively for studies within our Infectious Disease portfolio, including T-SPOT™.TB, T-SPOT™.CMV, and other T-SPOT technology-based assays, with plans to expand to additional therapeutic areas in the future.
-
Who is eligible to apply for Revvity ILS funding?
Principal Investigators and institutions conducting research of clinical relevance to Revvity's Infectious Disease products and related areas are eligible to apply. Qualified researchers who aim to advance clinical and scientific knowledge within Revvity's priority therapeutic areas are encouraged to submit applications.
-
What are the Principal Investigator's and Institution's roles and responsibilities?
In Revvity-supported studies, Revvity acts solely as a supporter while the investigator assumes the role of Sponsor-Investigator with full regulatory and ethical responsibilities.
-
Can I request funding for investigational devices not yet commercially available?
No, the Revvity ILS program does not provide funding for investigational devices or off-label use. Support is limited to commercially available diagnostic products and may include advanced instrumentation on a case-by-case basis, with financial assistance determined based on individual study scope and requirements.
-
When will I receive funding or products following approval?
Funding and product support will be distributed after the ILS contract is fully executed by all parties and the study receives IRB or IEC approval. Disbursement follows the milestone schedule established in the contract according to Revvity's standard payment terms.
For in vitro diagnostic use. This product is only available where licensed in accordance with law. Please contact your local representative for availability.
